Dr. John Cush RheumNow
2 years 7 months ago
Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/u2cf5hmTAE https://t.co/A4kdwG6eRm
Dr. John Cush RheumNow
2 years 7 months ago
JAK-pot: 46913 Rx courses on JAKi, TNFi, other MOA. Rx D/Cs for AEs:
- TNFi = JAKi (HR 1.0)
- Other MOA > JAKi (HR 1.11)
- TNFi < tofacitinib (0.81)
- TNFi > baricitinib (1.15)
- TNFi < JAKi; if >65yrs w/ CV risk (0.79) https://t.co/N5XnPjxAXO https://t.co/AnoKM7fzM7
Dr. John Cush RheumNow
2 years 7 months ago
What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/EqJRXSzrEs https://t.co/z5yuHDXUZ3
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui.
Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics.
Dr. John Cush RheumNow
2 years 7 months ago
Effective Treatments for Still's Disease
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).
https://t.co/Qi98OXyoLJ https://t.co/DCgXfs0Bot
Dr. John Cush RheumNow
2 years 7 months ago
Depression and RA
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.
https://t.co/nJZD4D2ByC https://t.co/ET3Xp9cK62
Dr. John Cush RheumNow
2 years 7 months ago
Vaccinations NOT linked to SLE risk. 17 studies (45 million) w/ F/U up to 2 yrs. No signif SLE risk:
- all vaccinations (OR=1.1; CI 0.86–1.5)
- HBV vax (OR=2.11; 1.11-4)
- HPV (OR=1.4; 0.88–2.3)
- Flu (OR=0.96; 0.82–1.1)
- COVID (OR=0.44; 0.18–1.2) https://t.co/YpxSYL97DM https://t.co/hsytm9UpDC
Dr. John Cush RheumNow
2 years 7 months ago
JAK inhibitors maybe an option in refractory Juvenile Dermatomyositis. Metanalysis of 26 reports (195 pts) JDM Rx w/ JAKi (median 5 rys); most Rx w/ tofacitinib (57%), ruxolitinib(27%), baricitinib (15%), w/ Improvement in 90%, 69%, 93%, respectively. https://t.co/acdlU13MfX https://t.co/fTFVvPz0EH
Dr. John Cush RheumNow
2 years 7 months ago
Lyme Disease 2022
The CDC has updated its Lyme disease surveillance report based on a new case definition. Compared to 2017–2019, the number of cases in 2022 rose by 69%.
https://t.co/iCAbSYbhsB https://t.co/7q8hCXV1CZ
JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs".
Dr. John Cush RheumNow
2 years 7 months ago
Increased Depression on Rheumatoid Arthritis
A Korean nationwide cohort study found that both seropositive and seronegative rheumatoid arthritis (RA) patients have a significantly higher risk of depression.
https://t.co/9AtlBrDTUJ https://t.co/vKEhBfkHQD
A follow-up analysis of a randomized clinical trial found that the use of calcium and vitamin D supplements among postmenopausal women was associated with decreased risk for cancer mortality, but increased risk for cardiovascular disease (CVD) mortality. The analysis is published in Annals of Internal Medicine.
Dr. John Cush RheumNow
2 years 7 months ago
Greek study of 160 #GCA pts (age 72 yrs) - all on Hi dose steroids (GC) @ start, 37% DMARD & 16% biologic. @ 2 Yrs, 42% D/C GC & 27% had Relapses. Predictors of relapse = LG vessel involv (OR=4.2), CV event (4.6) & higher initial GC doses (OR=1.04) https://t.co/FshaslTuSI https://t.co/y9uVgkR58Y
Dr. John Cush RheumNow
2 years 7 months ago
Starting MTX at higher or subcut. doses yields better ACR20 responses. Review of 12 trials & 1,566 pts, shows:
- higher initial MTX 25 mg (but more GI AEs)
- SC MTX more ACR20 resp (85% vs PO 77%)
- MTX non-response, success w/ SC MTX
https://t.co/01PuDpkUIF https://t.co/vXLWEp4srH
